CAR T therapies in multiple myeloma: unleashing the future - Cancer Gene Therapy

Nature·Mar 4

This story is reported by Nature. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

The Remarkable Proliferation of Cancer Immunotherapies

Ground Truths | Eric Topol·May 24

2

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)—real world experience from the US multiple myeloma immunotherapy consortium |

Nature·Mar 20

3

Incorporating mRNA therapeutics into biological treatments of hematologic malignancies

Frontiers·Oct 22

4

Harnessing the Potential of CAR T-Cell Therapy for Multiple Myeloma

Specialty Pharmacy Continuum·Dec 15

5

Continued need for autologous transplantation in relapsed myeloma

The Lancet·Sep 6

6

FDA Eases Access to CAR-T Therapies

Cancer Health·Jul 10

7

Personalized medicine & cell therapies

Abcam·Mar 1

8

Cell therapy’s future for fighting cancer is bright

Stanford Medicine Magazine·Jan 23